A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.
A 21-year-old woman with female pattern baldness has tried minoxidil, red light therapy, and supplements without success. She is considering spironolactone and seeking medical advice.
The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.
The conversation discusses using a microneedling device on the face after using it on the scalp, with suggestions to use a depth of 0.2mm for facial treatments. Caution and proper sterilization are advised due to the sensitivity of facial skin.
The post argues that Post-Finasteride Syndrome (PFS) is likely not real and suggests symptoms may be due to mental health issues or the nocebo effect. The conversation includes personal experiences with finasteride, highlighting both positive and negative effects, and emphasizes consulting doctors and using reliable sources for medication.
A user who had taken oral minoxidil for 6 months without seeing any results and the advice given in response, which included trying microneedling in combination with topical minoxidil, as well as seeking a dermatologist's opinion.
Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.
A user's 18-month hairline progress using minoxidil, finasteride, Nizoral, microneedling, and scalp massage. They share their routine and discuss treatment effectiveness and photo order confusion.
Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.